Puma Biotechnology (NASDAQ:PBYI) announces that
China’s National Medical Products Administration has approved Nerlynx
(neratinib) for the extended adjuvant treatment of adult patients with
early-stage human epidermal growth factor receptor 2 (HER2)-positive
breast cancer, following adjuvant therapy with trastuzumab (branded as
Herceptin by Roche).
Licensee CANbridge Pharmaceuticals will commercialize.
Shares up 5% premarket on light volume.
https://seekingalpha.com/news/3571252-puma-bios-nerlynx-okd-in-china
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.